Roth Capital Downgrades Inovio Pharmaceuticals (INO) to Sell

Roth Capital analyst Jonathan Aschoff downgraded Inovio Pharmaceuticals (NASDAQ: INO) from Neutral to Sell with a price target of $11.00.

For an analyst ratings summary and ratings history on Inovio Pharmaceuticals click here. For more ratings news on Inovio Pharmaceuticals click here.

Shares of Inovio Pharmaceuticals closed at $25.00 yesterday.

You May Also Be Interested In

• Jefferies Downgrades Calix (CALX) to Hold
• Jefferies Downgrades Enphase Energy (ENPH) to Hold, 'Still Muddling Through'
• JPMorgan Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Underweight